Getting to the roots of breast cancer

“It’s not enough to kill the dandelion blossom and stalk that appear above ground,” said Dr. Michael Lewis, assistant professor of molecular and cellular biology and a faculty member in the Lester and Sue Smith Breast Cancer Center at BCM. “You have to kill the root beneath the soil as well.”

In a study involving women with breast cancer, he and colleagues at BCM showed that while conventional anti-cancer drugs can kill the bulk of breast cancer tumors, they leave behind many of the breast cancer stem cells from which tumor cells arise, setting the stage for the tumor to come back.

“What we found is that one reason chemotherapy frequently does not work is that you kill the bulk of the tumor but leave many of the stem cells behind,” said Lewis. “It appears that these cells, by their nature, are resistant to the effects of anti-cancer drugs.”

However, treatment with the drug lapatinib and anti-cancer drugs appears to kill both the tumor and the stem cells, reducing the threat of relapse in patients whose tumors carry a protein marker called HER2, Lewis said.

In their study, he and colleagues took biopsies from the tumors of patients before and after treatment.

The study had two parts. In the first, 31 patients whose tumors did not have the HER2 marker received conventional chemotherapy. In the second part of the study, 21 patients whose tumors carried the HER2 marker, received treatment with lapatinib and two other common breast cancer drugs. (The HER2 marker meant that the tumors would be susceptible to lapatinib.)

The researchers stained the samples to highlight the subset of tumor cells that contained the stem cells, which can be identified by the presence of certain markers on the cell surface. This enabled them to estimate the percentage of stem cells in the biopsy. In addition, stem cells in the laboratory can grow into colonies of cells that scientists call mammospheres. Because of this, they could also measure those to estimate what proportions of stem cells are present in a sample.

In the group that received conventional chemotherapy, the number of tumor cells decreased markedly. However, after the treatment, the proportion of cancer stem cells (identified by special markers and mammosphere formation) to differentiated tumor cells was greater than before treatment. In other words, there was a higher percentage of stem cells because the chemotherapy killed the regular tumor cells but left stem cells behind.

In the group that received lapatinib, the number of tumor cells again decreased dramatically. However, the percentage of breast cancer stem cells did not change or even went down slightly (although the change did not reach statistical significance). Consistent with this, the percentage of patients who received lapatinib had significant tumor shrinkage at greater rates than that seen in patients who received conventional therapy.

“The tumor shrank dramatically,” said Dr. Jenny Chang, associate professor of medicine at BCM and medical director of the BCM Breast Care Cancer Center. “But in contrast to treatment with conventional chemotherapy, the relative proportion of stem cells did not go up. This means the stem cells were killed off with the same frequency as the bulk of the tumor. This is the first time this has been demonstrated.”

Finding drugs that work specifically against stem cells is a course for the future, said Lewis. He plans to start by characterizing the markers specific to breast cancer stems cells, and inhibiting them one-by-one.

Source: Baylor College of Medicine

Researchers create heart and blood cells from reprogrammed skin cells
Stem cell researchers at UCLA were able to grow functioning cardiac cells using mouse skin cells that had been reprogrammed into cells with the same unlimited properties as embryonic stem cells. The finding is the first to show that induced pluripotent stem cells or iPS cells, which don’t involve the use of embryos or eggs, can be differentiated into the three types of cardiovascular cells needed to repair the heart and blood vessels.
Chemo fails to root out breast cancer stem cells: study
While chemotherapy can remove breast cancer tumors, it fails to root out the stem cells that can revive the cancer, researchers said in a study published Tuesday.
Ovarian cancer stem cells identified, characterized
Researchers at Yale School of Medicine have identified, characterized and cloned ovarian cancer stem cells and have shown that these stem cells may be the source of ovarian cancer’s recurrence and its resistance to chemotherapy.
Charting the epigenome
Until recently, the chemical marks littering the DNA inside our cells like trees dotting a landscape could only be studied one gene at a time. But new high-throughput DNA sequencing technology has enabled researchers at the Salk Institute for Biological Studies to map the precise position of these individual DNA modifications throughout the genome of the plant Arabidopsis thaliana, and chart its effect on the activity of any of Arabidopsis’ roughly 26,000 genes.
Researchers find stem cell marker controls 2 key cancer pathways
Researchers at Georgetown University Medical Center have discovered that a gene associated with human breast stem cells can stimulate development of mammary cells by activating two critical cancer pathways. They say this finding, reported at the annual meeting of the American Association for Cancer Research (AACR), provides new evidence that breast cancer can arise from stem cells and that targeting this gene might provide a new way to treat cancers of the breast as well as other tumor types.
Study identifies gene involved in blood stem cell replication, movement
Researchers at the Joslin Diabetes Center have identified a gene that is responsible for the division and movement of marrow-derived, blood-forming stem cells, a finding that could have major implications for the future of bone marrow and blood cell transplantation.
New technique creates cancer stem cells
With a bit of genetic trickery, researchers at the Stanford University School of Medicine have turned normal skin cells into cancer stem cells, a step that will make these naturally rare cells easier to study.
Evidence now suggests eating soy foods in puberty protects against breast cancer
Evidence is growing from animal and human studies that genistein, a potent chemical found in soy, protects against development of breast cancer - but only if consumed during puberty, says a Georgetown University Medical Center researcher in the British Journal of Cancer published online today. The challenge now, she says, is for scientists to understand precisely why soy appears to provide a shield against the most common cancer in women.

Getting to the roots of breast cancer

Related stories:

News discussion: